1. Market Research
  2. > Business Services
  3. > Research and Development Market Trends
  4. > Histone Deacetylase Inhibitors: Emerging Markets

Histone Deacetylase Inhibitors: Emerging Markets

  • February 2014
  • -
  • BCC Research
  • -
  • 153 pages

REPORT HIGHLIGHTS

The global histone deacetylase inhibitor (HDI) market reached $153 million in 2011 and $223.2 million in 2012. This market is expected to be valued at $361.8 million in 2013 and $954.3 million by 2018, a compound annual growth rate (CAGR) of 21.4%.

This report provides:
An overview of the global market for histone deacetylase inhibitors.
Analyses of global market trends, with data from 2011 and 2012, estimates for 2013, and projections of CAGRs through 2018.
A breakdown of the market for histone deacetylase inhibitors not only by region, but by application as well.
Information pertaining to the manufacturing of HDIs as well information on the manufacturing companies involved.
Profiles of leading HDI companies in the market.

STUDY OBJECTIVES

The objective of this BCC Research study was to evaluate, analyze and predict the prospective histone deacetylase inhibitors (HDIs) market, as well as the progress of the ongoing clinical developments of numerous candidates. The report portrays the present HDI niche market and projects a provisional picture of future market escalation derived from the current products, the impressive HDI pipelines, successful research and development activities, the strategic plans of larger biopharmaceuticals and pharmaceuticals, and the present and prospective market dynamics.The report presents a holistic view on the present market size based on the two approved HDI products: vorinostat (Zolinza) and romidepsin (Istodax). It also interprets the anticipated market size, revenue assessment, prospective products based on classic and second-generation histone deacetylase inhibitors, market leaders, market shares and the drivers shaping the HDIs market. An outline of the innovative platforms, technologies and prospective candidates for the present and potential market based on their potency in various diseases are detailed. It is too early to project the market trend from just two approved products, so the prospective market is presented in a summarized manner derived from the successful and promising clinical developments of late-stage products. The opportunities, limitations, patent analysis, new developments and regulatory aspects are detailed to the extent of the scope of this report. Profiles of reputed and budding companies involved in the development of HDIs are also provided.The sales data for the two products is obtained from the relevant sources, including the manufacturing company’s annual reports. The data is analyzed for the period from 2011 through October 2013. A 2018 revenue projection is also provided. The report analyzes the regional sales data for North America, which is comprised of the U.S. and Canada; Europe; and the emerging markets for this period.

REASONS FOR DOING THIS STUDY

Drugs that target epigenetic alterations have recently presented clinical potential, and histone deacetylase inhibitors comprised one such genre of drugs. The prospect of using histone deacetylase inhibitors in the treatment of cancer is already recognized through vorinostat and romidepsin. The potency and efficacy of these drugs and other candidates for various diseases, including cancer, heart ailments and human immunodeficiency virus (HIV) infection, are being investigated. The progress in the research and development (R&D) of the histone deacetylase inhibitors in recent years is significant. This report offers a synopsis of the latest exploratory work and market opportunities for the producers of HDIs from the viewpoint of new products, their prospective application on target diseases, the latest clinical developments and late-stage candidates. Furthermore, it provides details of scientific researches that would be helpful for scientists and research organizations for the advancement of their R&D work.The present market dynamics including the prospective pipeline, collaboration and joint ventures, focused researches and most importantly the need of drugs for the fatal diseases such as cancer, neurodegenerative diseases and others are driving the activities in the histone deacetylase inhibitors space. There is enormous opportunity for this industry to develop and commercialize products for a huge patient base worldwide and this report presents the details meticulously.

CONTRIBUTIONS OF THE STUDY AND FOR WHOM

This report accentuates two major aspects. One is the inevitability of histone deacetylase inhibitors to treat diseases, most of which currently have no proper cure. The other is the opportunity in a market that lacks very few commercialized products. There are currently only four drugs approved in the epigenetic drug market. This study presents the key developments of the histone deacetylase inhibitors industry that would be useful for the manufacturers, producers, researchers, research universities, and other government and non-government organizations.

SCOPE OF THE STUDY

BCC Research carried out the market assessment of the present niche market for histone deacetylase inhibitors, the geographic breakdown of sales data, current and prospective applications, regulatory aspects, market projection, advances and restraints, patent analysis, clinical developments, market leaders and market share for histone deacetylase inhibitors.The sales data for the global markets is authenticated for the present and anticipated values through statistical analysis. Correspondingly, regional data was measured for respective regions. The product and candidate information, technologies and platforms are based on their prospective application and practicability.

METHODOLOGY

BCC Research collected all pertinent information for this study through primary and secondary research methodologies. In the process, BCC Research interviewed industry experts, including producers of histone deacetylase inhibitors, scientists and other industry veterans. Searches were conducted in various information sources. Market projections echo the probable unit prices, usage of HDIs, the present-day economy and plausible HDI applications.

Table Of Contents

Histone Deacetylase Inhibitors: Emerging Markets
Chapter- 1: INTRODUCTION
STUDY OBJECTIVES
REASONS FOR DOING THIS STUDY
CONTRIBUTIONS OF THE STUDY AND FOR WHOM
SCOPE OF THE STUDY
METHODOLOGY
INFORMATION SOURCES
ABOUT THE AUTHOR
RELATED BCC RESEARCH REPORTS
BCC RESEARCH ONLINE SERVICES
DISCLAIMER
Chapter- 2: EXECUTIVE SUMMARY
Table Summary : GLOBAL HISTONE DEACETYLASE INHIBITOR MARKET BY REGION, THROUGH 2018
Figure Summary : GLOBAL HISTONE DEACETYLASE INHIBITOR MARKET BY REGION, 2011-2018
Chapter- 3: OVERVIEW
HISTONE DEACETYLASES AND HISTONE ACETYLASES
HISTONE DEACETYLASE INHIBITORS
CLASSIFICATION
OTHER HISTONE DEACETYLASE INHIBITORS
ACETYLATION OF NON-HISTONE PROTEINS
EMERGING TARGETS
Chapter- 4: REGULATORY ASPECTS
VORINOSTAT
ROMIDEPSIN
REGULATORY DEVELOPMENTS FOR HISTONE DEACETYLASE INHIBITORS
Chapter- 5: NEW DEVELOPMENTS
NEW COLLABORATIVE TRAILS AND FUTURE ACTIVITIES
Table 3 : DEVELOPMENT STAGES FOR HISTONE DEACETYLASE INHIBITORS
Table 4 : NEW DEVELOPMENTS IN THE RESEARCH PIPELINE FOR HISTONE DEACETYLASE INHIBITORS AS MONOTHERAPIES, OCTOBER 2013
Table 5 : NEW DEVELOPMENTS IN THE RESEARCH PIPELINE FOR HISTONE DEACETYLASE INHIBITORS AS COMBINATION THERAPIES, OCTOBER 2013
Table 6 : ONGOING TRIALS FOR MAJOR HISTONE DEACETYLASE INHIBITORS AS MONOTHERAPIES AND COMBINATION THERAPIES, OCTOBER 2013
Chapter- 6: HISTONE DEACETYLASE INHIBITOR MARKET ANALYSIS
MARKET BY TYPE
MARKET BY REGION
PROSPECTIVE FUTURE HISTONE DEACETYLASE INHIBITORS MARKET
INDUSTRY STRUCTURE
Chapter- 7: MARKET BY APPLICATION
MARKET BY APPLICATION
PROSPECTIVE APPLICATIONS FOR HISTONE DEACETYLASE INHIBITORS
RESEARCH AND DEVELOPMENT
Table 15 : HISTONE DEACETYLASE INHIBITOR TYPES BY APPLICATION
Table 16 : HISTONE DEACETYLASE INHIBITOR COMBINATIONS WITH THERAPIES BY APPLICATION
Chapter- 8: PATENT ANALYSIS
PATENTS BY YEAR
PATENTS BY HISTONE DEACETYLASE INHIBITOR CATEGORY
PATENTS BY HISTONE DEACETYLASE INHIBITORS TYPE
PATENTS BY COUNTRY
PATENTS BY COMPANY
PATENTS BY ASSIGNEE
Chapter- 9: CURRENT SITUATION
RESEARCH AND PROGRESS
NEW TECHNOLOGIES AND PLATFORMS IN HISTONE DEACETYLASE DEVELOPMENT
FACTORS AFFECTING THE HISTONE DECAETYLASE MARKET
CURRENT DRIVERS OF HISTONE DEACETYLASE MARKET
COLLABORATIONS AND ACQUISITIONS
Chapter- 10: COMPANY PROFILES
4SC
ACETYLON PHARMACEUTICALS INC.
ARNO THERAPEUTICS INC.
ASAN MEDICAL CENTER
ASTELLAS PHARMA INC.
ASTRAZENECA PLC
CELGENE CORPORATION
CELLCEUTIX CORPORATION
CELLERON THERAPEUTICS LTD.
CHROMA THERAPEUTICS LTD.
COLUMBIA UNIVERSITY
CRYSTALGENOMICS INC.
CURIS INC.
CYCLACEL PHARMACEUTICALS
CYCLEX CO. LTD.
DIAXONHIT GROUP
ENVIVO PHARMACEUTICALS
GENENTECH INC.
GEORGETOWN UNIVERSITY
GEORGIA TECH RESEARCH CORP.
GILEAD SCIENCES INC.
IMPERIAL INNOVATIONS LTD.
ITALFARMACO S.P.A.
JANSSEN PHARMACEUTICA NV
KARUS THERAPEUTICS LIMITED
LES LABORATOIRES SERVIER
LIXTE BIOTECHNOLOGY HOLDINGS INC.
MAYO CLINIC
MEI PHARMA INC
MEMORIAL SLOAN-KETTERING CANCER CENTER
MERCK and CO. INC.
MIRATI THERAPEUTICS
NATIONAL CANCER INSTITUTE
NATIONAL COMPREHENSIVE CANCER NETWORK
NATUREWISE BIOTECH and MEDICALS CORPORATION
NOVARTIS INTERNATIONAL AG
OCEANYX PHARMACEUTICALS INC.
OHIO STATE UNIVERSITY COMPREHENSIVE CANCER CENTER
ONCOLYS BIOPHARMA INC.
PFIZER
PHARMACYCLICS
PROMEGA CORPORATION
REPLIGEN CORPORATION
ROSWELL PARK CANCER INSTITUTE
SHAPE PHARMACEUTICALS
SHENZHEN CHIPSCREEN BIOSCIENCES
SPECTRUM PHARMACEUTICALS
SYNDAX PHARMACEUTICALS INC.
TITAN PHARMACEUTICALS INC.
TOPOTARGET A/S
UNIVERSITY OF ILLINOIS: OFFICE OF TECHNOLOGY MANAGEMENT
UNIVERSITY OF SOUTHAMPTON HIGHFIELD
UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER
YAKULT HONSHA CO. LTD.
Chapter- 11: ABBREVIATIONS

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2010-2016

Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2010-2016

  • $ 2995
  • Industry report
  • September 2016
  • by Currentpartnering

The Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2016 report provides comprehensive understanding and unprecedented access to the collaborative R&D deals ...

Scientific Research and Development (R&D) in Physics, Engineering, Telecommunications and Computers Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts: NAIC 541712

Scientific Research and Development (R&D) in Physics, Engineering, Telecommunications and Computers Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts: NAIC 541712

  • $ 1995
  • Industry report
  • November 2016
  • by Plunkett Research

Scientific Research and Development (R&D) in Physics, Engineering, Telecommunications and Computers Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2023, NAIC ...

Global Epoxy Resins Electrical And Electronics Market Forecast 2016-2022.

Global Epoxy Resins Electrical And Electronics Market Forecast 2016-2022.

  • $ 1950
  • Industry report
  • November 2016
  • by Inkwood Research

KEY FINDINGS Epoxy Resins are a class of reactive polymers and pre-polymers that contain epoxide group. This material has shown extensive utility in various applications such as paints and coatings, adhesives, ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.